No abstract

No abstract

A new unsymmetrical s-tetrazine derivative, namely 4-({2-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-yl]hydrazin-1-ylidene}methyl)phenol (DPHM), CHNO, was synthesized based on 3-(3,5-dimethylpyrazol-1-yl)-6-hydrazinyl-s-tetrazine (DPHT). The structure was characterized by elemental analysis and single-crystal X-ray diffraction. Crystal structure determination shows that DPHM crystallizes in the monoclinic P2/c space group with high coplanarity and a zigzag layered structure. In addition, its thermal behaviour was investigated by DSC and TG-DTG methods. The thermal safety of DPHM was evaluated by self-accelerating decomposition temperature (T), critical temperature of thermal explosion (T), entropy of activation (ΔS), enthalpy of activation (ΔH) and free energy of activation (ΔG). Meanwhile, the kinetic parameters and specific heat capacity of DPHM were also determined. The results show that DPHM has better stability and detonation properties than 3-(2-benzylidenehydrazin-1-yl)-6-(3,5-dimethylpyrazol-1-yl)-s-tetrazine (DAHBTz), due to the introduction of a hydroxy group, which increases the number of hydrogen-bond interactions and improves the stability and density of DPHM. This study demonstrates that the performance of an explosive can be optimized through structural modification.

Objective: To investigate the clinical efficacy of Bolus of Six Drugs Including Rehmannia (Liuwei Dihuang pill) as an adjunct to metformin in the treatment of senile Type-2 diabetes mellitus and its influence on insulin resistance, inflammatory factors and blood glucose-related indexes. Methods: This is a Retrospective study. Eighty senile Type-2 diabetes mellitus admitted to Baoding Hospital of Traditional Chinese Medicine from January 2019 to December 2021 were enrolled and divided into two groups using the random number method. Patients in the control group were given oral metformin, while those in the observation group were treated with Bolus of six Drugs Including Rehmannia as an adjunct to metformin. The clinical efficacy, blood glucose-related indicators, insulin-related indicators, inflammatory factors-related indicators and adverse drug reactions were compared between the two groups. Results: The overall response in the observation group was higher than that in the control group(P<0.05). After treatment, the levels of FPG, 2hPG and HbA1 being more significantly lower in the observation group than that in the control group(P<0.05). Moreover, the levels of FINS, HOMA-IR and HOMA-IS were all significantly improved in the observation group than that the control group (P<0.05). HOMA-β levels in the observation group were significantly higher than those in the control group (P<0.05). The levels of TNF-α, IL-6 and IL-8 in the observation group were significantly lower than those in the control group (P<0.05). Conclusion: Bolus of six Drugs Including Rehmannia as an adjunct to metformin is a regimen with satisfactory safety profile for the treatment of senile Type-2 diabetes mellitus. doi: https://doi.org/10.12669/pjms.39.5.7262 How to cite this: Li N, Yao Y, An E. Clinical Efficacy of Bolus of Six Drugs Including Rehmannia as an Adjunct to Metformin in the Treatment of Senile Type-2 Diabetes Mellitus and its Influence on Insulin Resistance, Inflammatory Factors and Blood Glucose-related Indicators. Pak J Med Sci. 2023;39(5):---------. doi: https://doi.org/10.12669/pjms.39.5.7262 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.